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Non-allopathic adjuvant management of osteoarthritis 
by alkalinisation of the diet
Background: Osteoarthritis (OA) is a chronic condition. Nonsteroidal anti-inflammatory drugs 
recommended for treatment have serious adverse effects. A compelling body of anecdotal 
evidence alerted the authors to the therapeutic potential of dietary supplementation with 
Multiforce® (MF) Alkaline Powder for relief of OA symptoms.
Aim: The aim of the study was to test the hypothesis that dietary supplementation with MF 
relieves clinical signs and symptoms of OA of the hands.
Setting: The study was done at the MEDSAC hospital in Somerset West, Western Cape, South 
Africa.
Methods: The research was conducted in two stages. An open interventional study (n = 40) 
confirmed the notion that MF 7.5 g twice daily is likely to be an effective alternative or adjunct 
for relief of symptoms of OA of the hands. The main study was conducted with 100 eligible, 
consenting volunteers (aged 47–89 years) according to a randomised, placebo-controlled, 
crossover design. Study duration was 56 days, 28 days per regimen; crossover to alternate 
regimens took place on day 28.
Results: Compared to placebo, MF intake over 28 days was associated with significant reductions 
( p < 0.005) in pain, tenderness and stiffness of interphalangeal and metacarpophalangeal joints 
of the hand. Confirmation of systemic alkalinisation by MF, which is rich in organic anions 
in the form of citrate salts, was reflected by a significant and sustained increase in urine pH.
Conclusion: A dietary supplement, Multiforce® Alkaline Powder, containing citrate salts 
which are converted into bicarbonate in vivo, was efficacious and safe as sole therapeutic 
intervention, significantly attenuating OA-associated signs and symptoms of the hands.
Gestion adjuvante non-allopathique de l’ostéoarthrite  par alcalinisation de l’alimentation.
Introduction: L’ostéoarthrite (OA) est une condition chronique. Les médicaments anti-
inflammatoires non-stéroïdes – piliers du soulagement symptomatique – peuvent causer des 
effets nocifs graves, surtout chez les personnes âgées. Un ensemble de preuves anecdotiques 
probantes ont attiré l’attention des auteurs sur le potentiel thérapeutique du supplément 
alimentaire du Multiforce® Alkaline Powder (MF) pour le soulagement des symptômes 
d’ostéoarthrite.
Objectifs: Le but de l’étude était de tester, au moyen d’essais contrôlés randomisés, l’hypothèse 
que le supplément alimentaire avec MF soulage les signes et les symptômes cliniques de l’OA 
des mains.
Méthodes: La recherché a été faite en deux phases. Une étude ouverte interventionnelle 
(n = 40) a confirmé la notion que 7.5 g de MF deux fois par jour est une alternative ou un 
supplément efficace pour le soulagement des symptômes d’ostéoarthrite des mains. Là-dessus 
l’étude principale a été faite sur 100 volontaires admissibles et consentants (47−89 ans), selon 
un plan croisé, randomisé et contrôlé par placebo; n = 50 par groupe de traitement A et B 
(verum n = 50- groupe A, et placebo n = 50- groupe B, spécifiant quel traitement a été fait en 
premier). La durée de l’étude était de 56 jours, 28 jours par régime. La transition aux régimes 
alternés s’est faite le 28ème jour. Les visites cliniques ont eu lieu tous les quinze jours.
Résultats: Comparativement au placebo, la prise de MF pendant 28 jours a montré des 
réductions significatives des douleurs (p < 0.005), de la sensibilité et de la raideur des 
articulations inter-phalangiennes et métacarpo-phalangiennes de la main. La confirmation 
d’une alcalinisation par MF, riche en anions organiques sous forme de sels de citrate, a été 
vérifiée par une augmentation importante et prolongée du pH de l’urine. La prise de MF a été 
bien tolérée.
Conclusion: Le supplément alimentaire, Multiforce® Alkaline Powder, contenant des sels 
de citrate qui sont convertis en bicarbonate in vivo, est efficace et sans danger quand il 
sert de seule thérapie, et il atténue considérablement les signes et les symptômes associés à 
l’ostéoarthrite des mains. 
Read online: 
Scan this QR 
code with your 
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to read online.
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Introduction
Osteo-arthritis (OA) is a major cause of morbidity, affecting 
60% of men and 70% of women over the age of 65 years.1 
Current therapeutic approaches, including allopathic 
(Western) medicine, fail to prevent initiation and progression 
of OA, and some have life-threatening side-effects. The 
rapidly rising rates of complex, chronic disease are creating 
an unsustainable burden on the national economy in both 
direct (e.g. treatment) and indirect (e.g. lost productivity) 
costs.
These chronic and degenerative diseases cannot be effectively 
treated with drugs alone. As a matter of fact, chronic drug 
use for these conditions is not only costly but often has 
serious side-effects. Popular analgesics and nonsteroidal 
anti-inflammatory drugs (NSAIDs) such as celecoxib, 
diclofenac, ibobrufen, naproxen and aspirin have confirmed 
risk for heart disease and internal bleeding.2,3 Paracetamol 
can damage the liver. Allopathic medicines often do not cure 
these diseases, but rather mask the symptoms.
The incidence of OA increases with age, and ageing 
patients present with comorbidities that add to the 
complexity of treatment. Degeneration of joint cartilage 
is still the most important pathophysiological feature 
of OA. Tissues surrounding the joints, such as muscles, 
bones, tendons and ligaments, are also involved in the 
disease process. Recommendations for management of 
OA comprise non-pharmacological and pharmacological 
approaches. Non-pharmacological interventions include 
education and self-management, referral to a physical 
therapist, aerobic muscle-strengthening and water-based 
exercises, weight reduction, diet interventions, walking 
aids, knee braces, therapeutic footwear and insoles, thermal 
modalities, transcutaneous electrical nerve stimulation 
and acupuncture. Pharmacological treatments consist 
of paracetamol, systemic and topical cyclo-oxygenase-2 
(COX-2) non-selective and selective inhibitors, classified 
as NSAIDs, topical capsaicin, intra-articular corticosteroids 
and hyaluronates, glucosamine and/or chondroitin 
sulphate and diacerin for possible structure-modifying 
effects, and use of opioid analgesics and tramadol for 
the treatment of refractory pain.4,5 Methotrexate, which 
has immunosuppressive and anti-inflammatory effects, 
is promising, but this drug may have serious side-
effects, including liver disease, lung inflammation, 
increased susceptibility to infection, and suppression of 
blood cell production in the bone marrow. Studies with 
disease-modifying drugs in management of OA, such as 
bisphosphonates with the aim of inhibiting increased bone 
turnover, did not produce positive results.1
Long-term use of systemic NSAIDs to relieve OA symptoms 
could cause serious adverse events, such as gastro-intestinal 
bleeding, renal damage, and induction or aggravation of 
bronchial asthma and cardiovascular complications.2 The 
effect of COX-2 inhibitors on renal function is still tenuous. 
Of great concern has been the voluntary withdrawal of 
rofecoxib (Vioxx®) from the market in 2004 because of an 
increased risk of serious cardiovascular events, including 
heart attacks and stroke amongst patients taking Vioxx® 
compared to patients receiving placebo.6
Dietary considerations
The typical ‘Western diet’ is considered acidogenic due to 
the greater acid load contained in animal products, and is 
low in fruit and vegetables, resulting in a state of overlooked 
low-grade chronic, compensated metabolic acidosis.7 The 
ensuing acidotic stress and hypoxia may play a role in the 
pathophysiology of OA.8 In response to states of diet-derived 
metabolic acidosis, the kidney implements compensating 
mechanisms to restore the acid-base balance.
In South Africa there is compelling anecdotal evidence that 
an alkaline diet supplement, Multiforce® (MF) Alkaline 
Powder, has beneficial effects in patients with primary OA 
prompted this research to objectively explore the influence 
of dietary supplementation with MF on symptoms and signs 
of OA.
Aim
The aim of the study was to test, by means of a randomised 
controlled trial, the hypothesis that dietary supplementation 
with MF relieves clinical signs and symptoms of OA of the 
hands.
Research methods and design
The research comprised two stages, a pilot study and the 
main study.
In the pilot, a single-centre, open study of the efficacy and 
safety of MF in participants (n = 40) with OA revealed 
significant improvements (p < 0.005) in all parameters 
assessed. Side-effects were negligible (unpublished data).
The pilot study was followed by a single-centre, double-
blind, placebo-controlled crossover study of the efficacy and 
safety of MF in participants with OA of the hands (n = 100), 
which is the subject of this article.
Both protocols were approved by the Ethics Committee for 
Human Research of Stellenbosch University (SU Ethics ref 
no: 10/02/009).
Study population
One hundred (100) consenting and responsible adult male 
and female volunteers (47–89 years of age; mean 65 years) 
with symptoms and signs of OA of the hands (left or right), 
with or without current allopathic treatment, fulfilling 
the inclusion criteria were recruited in Somerset West and 
surrounding areas.
For inclusion participants had to be able to understand and 
follow the instructions of the protocol; be mobile enough 
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to attend visits to the clinic; give informed consent; be 
willing, committed, and able to return for all clinic visits 
and complete all study-related procedures; be able to 
engage in telephone communication; be compliant with 
the American Rheumatism Association classification of 
OA;9 and be able to complete a daily pain visual analogue 
scale (VAS) and the validated Stanford Health Assessment 
Questionnaire (HAQ) 20-item disability scale at each of the 
six visits. The two-page HAQ-DI (disability index)10 was 
used.
Exclusion criteria were, inter alia, gout or serum uric acid 
equal to or greater than 0.45 mmoL/L, rheumatoid arthritis 
or high-sensitivity C-reactive protein (hs-CRP) > 20 mg/dl, 
known or suspected current infection or recurrent infectious 
disease of a joint, immunosuppressive therapy, history of 
demyelinating disease or symptoms suggestive of multiple 
sclerosis, psoriasis, intra-articular, intramuscular or 
intravenous glucocorticoid therapy eight weeks prior to the 
screening visit, glomerular filtration rate of < 30 mL/min (as 
per the Modification of Diet in Renal Disease index), history 
of acute or recurrent urinary tract infections, ‘abnormal’ 
clinical chemistry and haematology values, such as serum 
transaminases and alkaline phosphatase > 2 x upper limit of 
normal, full blood count outside normal limits, and abnormal 
serum electrolyte levels.
In addition, patients with any other arthritic or medical 
condition that in the opinion of the investigator could 
compromise participation or interfere with evaluations were 
excluded, as were those with a history of drug abuse within 
the five years prior to the screening visit, a history of alcohol 
abuse or current intake of 21 or more alcohol-containing 
drinks per week, and any investigational drug taken within 
three months or five drug half-lives, whichever was the 
longer period, prior to screening.
Washout period
Prior to randomisation eligible participants were instructed 
to discontinue any medication (over-the-counter or 
prescription) used for relief of pain or stiffness of joints for 
14 consecutive days, and preferably with the consent of a 
prescribing physician. At completion of the study patients 
could be switched back to their pre-study medication 
regimen.
Screening visit (visit 1)
At the screening visit participants provided informed 
consent and underwent clinical and laboratory evaluation 
for trial inclusion. In addition a urine dipstick analysis was 
performed and urine pH measured by means of a semi-
automated colorimetric method (Siemens kit) within two 
hours of voiding. Patients were instructed not to change their 
diet in any way during the study period. Random urinary 
pH was an indication of the dietary acid load; 85% of study 
participants had a low urinary pH, indicating an acidogenic 
diet.11
Trial medication
Study-related medication (MF verum and matching 
placebo) was supplied by Bioforce SA Pty (Ltd). Each 7.5 g 
of MF Alkaline Powder (verum) contains magnesium 
hydrogenium phosphate 244 mg, calcium citrate 145 mg, 
potassium bicarbonate 783 mg, magnesium citrate 315 mg, 
potassium citrate 870 mg, dicalciumphosphate 2-hydrate 
973 mg, organic plant calcium, acerola extract and mannitol, 
and delivers about 250 mg of elemental calcium. The 
placebo contained mannitol, polydextrose, pirosil, xanthan 
gum, maize starch and beetroot leaf mix, and was designed 
and manufactured by Powdermix Technologies (Pty) Ltd 
(www.powdermix.co.za).
Trial medication was provided in sachets containing 7.5 g of 
product. The contents of one sachet, suspended in 200 mL of 
non-carbonated water at room temperature, were ingested 
twice daily; that is 30 minutes before breakfast (am) and 
30 minutes before supper (pm). Patients were instructed to 
take the medication (verum or placebo) for a period of 28 days, 
after which they immediately switched to the alternative 
treatment for another 28 days. The participants and evaluating 
physician were blinded regarding the identity of treatments.
Dietary intervention
Patients were encouraged to continue with their individual 
standard diets for the duration of the study, the only 
intervention being supplementation with MF.
Biochemical assessment of inflammation
At each visit hs-CRP measurement was performed to 
evaluate whether subjects with long-established OA had 
active inflammation, and to assess whether MF intervention 
had any anti-inflammatory effects.12
Assessment of joints
At the end of the washout period assessment of generalised 
pain was done according to a VAS. Pain assessment was done 
on a 10-point scale, which is a double-anchored horizontal 
line standardised to 15 centimetres in length, where each end 
represents opposite ends of a continuum. This line is labelled 
0 = no pain at the left anchor point and 10 = severe pain at 
the right anchor point. Patients were instructed to place a 
vertical mark on the line to indicate the severity of their pain.
The interphalangeal or metacarpophalangeal joints of the 
hand were evaluated separately. One joint only served as 
outcome target; that is left or right hand (interphalangeal 
or metacarpophalangeal joints), whichever was the worst 
affected. The affected joints were assessed for tenderness on 
pressure, and for pain and stiffness upon active or passive 
movement. Tenderness, pain and stiffness were recorded on 
a 4-point scale as follows:
• 0 = Patient felt no tenderness/pain/stiffness.
• 1 = Patient complained of pain/stiffness.
Page 4 of 7 Original Research
http://www.phcfm.org doi:10.4102/phcfm.v7i1.780
• 2 = Patient complained of pain and winced.
• 3 = Patient complained of pain, winced and withdrew the 
hand.
Clinical assessments were performed by the same investigator 
throughout the study.
Rescue medication
Participants were allowed to use oral paracetamol up to 
a maximum of 2 g daily for pain during the washout and 
trial periods. In the event that the intake of maximum daily 
quantities was exceeded on five consecutive days, patients 
were to be withdrawn from the study as ‘treatment failures’. 
No other analgesics or NSAIDs were allowed during 
the washout and trial periods. Reconciliation of rescue 
medication issued and used took place at visits 4, 5 and 6, 
and at any time of termination of participation.
Concomitant medication
Participants were allowed to continue with existing chronic 
medication if there was no suspected interaction between MF 
and such regimens.
Study flow sequence
Day 1 (visit 2)
Baseline clinical and biochemical data, including urine pH, 
were collected. Instruction was given regarding quality of 
life and VAS scale scoring. Randomisation was done to either 
MF verum or MF placebo (n = 50 per treatment group).
Day 14 (visit 3)
QOL and pain-scale data were collected. Joint parameters 
were clinically assessed. Urine pH was determined. Side-
effects were recorded. Rescue medication was reconciled and 
reissued.
Day 28 (visit 4)
Clinical and biochemical evaluation was done as on day 1 
(visit 2). Day 14 (visit 3) procedures were repeated with a 
crossover to the alternate regimen (verum ⇄ placebo).
Day 42 (visit 5)
Evaluations were done as on day 14 (visit 3).
Day 56 (visit 6)
This visit signalled the end of the study. Evaluations were 
done as per day 28 (visit 4). Patients who chose to do so 
switched back to pre-study pharmacotherapy.
Statistical analysis
For statistical analysis of the data a mixed-model repeated 
measures analysis of variance was conducted, with group 
and time as fixed effects and the patients as random effects. 
For post-hoc pairwise comparisons, Fisher’s least significant 
difference (LSD) was used. Analyses were conducted 
using the VEPAC module of Statistica 12 data analysis 
software system (StatSoft, Inc., 2014; www.statsoft.com). A 
significance level of 5% (p < 0.05) was used as the guideline 
for determining significant changes.
Results
One hundred and fifty-nine patients were screened for OA of 
the hands, and 100 who fulfilled the inclusion criteria were 
enrolled in the study. They were randomly assigned into two 
groups, A and B (verum n = 50 group A, and placebo n = 50 
group B, specifying which treatment came first). Drop-outs 
were not replaced. Two patients, one from each treatment 
group, dropped out because they relocated, and 98 patients 
completed the trial. Eighty-eight per cent of participants 
were female.
All participants had primary OA of the IP or MP joints of the 
hands.
Acceptability and tolerance of supplement
No serious adverse events occurred. Three patients reported 
mild diarrhoea whilst on the verum intervention. Overall 
acceptability was good.
Value of the Stanford HAQ
During the two-month intervention trial no significant 
changes were found in functional ability in dressing and 
grooming, arising, eating, walking, hygiene and reach. 
Most participants had only difficulty in grip strength 
(opening jars and taps) and in performing certain 
household activities and gardening. Although they did 
experience some improvement in the function of the 
hands on the verum, this was not statistically significant. 
It is clear that this questionnaire is more appropriate for 
patients with rheumatoid arthritis with severe functional 
disability, and it did not help in assessing the influence of 
the intervention on OA in those with longstanding OA and 
no other serious functional disabilities. Patients with OA 
of the hands have low functional disability not amenable 
to change.
Efficacy
The influence of the verum (MF) intervention compared to 
placebo on efficacy parameters is depicted in Figure 1 (a–d).
The MF verum regimen, prior to or following the placebo 
regimen, resulted in significant (p < 0.005) improvement 
in the four efficacy variables evaluated. Significance was 
reached within two weeks of treatment. Placebo did not 
exhibit any positive outcome (p > 0.005) at any time. Of note 
is the observation that switching from verum to placebo was 
not accompanied by worsening of the signs and symptoms 
of OA, and that verum treatment had apparently not reached 
optimum therapeutic efficacy after four weeks.
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FIGURE 1: VAS pain score on 10-point scale, and clinical assessment of interphalangeal or metacarpophalangeal joint tenderness, pain, and stiffness on a 4-point scale 
(0–3). Vertical bars denote 0.95 confidence intervals. Blue: placebo followed by verum; red: verum followed by placebo. The letters on Figures 1 and 2 represent the 
results from the post hoc tests where all means were compared pairwise to determine possible significant differences. In this way any mean on the graph can be compared 
to any other mean. If the annotations share just one letter (e.g. a vs. a, b vs. b or a vs. ab), then the corresponding p-value comparing the two means will be > 0.05. If the 
annotations share no letters (e.g. a vs b or a vs bc) then the corresponding p-value comparing the two means will be < 0.05.
Urine pH
The group that received placebo first followed by a switch 
to verum after four weeks showed no significant change 
in urine pH, but the switch made after four weeks (visit 
4) was followed by a significant and sustained increase 
in pH.
Conversely, in the group that received verum first, followed 
by placebo after four weeks, urine pH increased significantly, 
but when the switch to placebo was made (visit 4) urine 
pH returned to pre-verum values. These data clearly 
distinguished verum from placebo and served as a surrogate 
endpoint for gauging study compliance with regard to 
adherence to treatment regimens (see Figure 2).
Inflammatory marker
There was no change in hs-CRP during the study period 
of two months. The median value for hs-CRP at baseline 
was 2.9 mg/dL (25th – 75th percentile 0.3–23). Traditionally 
CRP has been used to distinguish systemic inflammatory 
disorders such as rheumatoid arthritis from OA. However, 
multiple studies have demonstrated that hs-CRP is 
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FIGURE 2: Mean urine pH values determined at baseline and subsequent 
fortnightly clinic visits. Blue: placebo followed by verum; red: verum followed 
by placebo.
modestly elevated in the plasma of patients with OA 
compared to age-matched controls. Whilst hs-CRP levels in 
rheumatoid arthritis are typically > 15 mg/L, levels in OA 
typically range from 3 to 8 mg/L.12 This may indicate that 
the preparation does not influence inflammation, or it may 
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be that the volume of the synovium in longstanding OA is 
too small to influence it.
Rescue medication
We investigated the use of the rescue medication and it 
was found not to be different in the placebo and verum 
groups.
Discussion
The results of this randomised placebo-controlled study 
involving 98 participants corroborate the findings of the 
pilot study, namely that the dietary supplement MF, at a 
dose of 7.5 g twice daily, reduces signs and symptoms of 
OA in hands significantly, and that ingestion of MF in this 
manner is associated with alkalinisation of urine. It is thus 
a tenable deduction that the pilot study was devoid of a 
placebo effect.
Efficacy of MF reached significance within two weeks and 
was sustained over the four weeks of treatment, regardless 
of the order of randomisation. It is also apparent that efficacy 
levels had not reached steady state after four weeks, which 
suggests that MF could provide even more pronounced 
relief if used continuously. This theory is supported by the 
observation that MF treatment appeared to result in a ‘carry-
over’ effect, deduced from the finding that improvement 
in signs and symptoms of OA was sustained even after 
crossover from verum to placebo.
A limitation of the study is the short intervention time, and 
that we did not do a diet recall during the study. Dietary 
restrictions and modifications were not enforced in this 
study. Therefore it is reasonable to deduce that alterations 
in the OA signs and symptoms and urine pH were induced 
by dietary supplementation with MF, which is rich in 
organic anions, notably citrate salts, which are converted 
into bicarbonate systemically. Although the mechanism(s) 
whereby MF supplementation provided clinical relief 
of OA of the hands is not clear, the acidic extracellular 
environment may lead to increased intracellular acid loads 
experienced by chondrocytes. Extracellular factors such as 
acidosis may affect articular chondrocytes and this may 
have implications for disease progression and potential 
therapeutic intervention. Articular cartilage is a highly 
specialised tissue designed to allow pain-free, friction-
less movement across joints. Mature cartilage is avascular, 
relatively hypoxic and acidic and thus provides an unusual 
and challenging environment to the resident cell, the 
chondrocyte.
In joint diseases such as OA and rheumatoid arthritis oxygen 
levels are reduced further from increased consumption 
by inflammatory cells, and reduced delivery of oxygen to 
synovial fluid due to joint capsule fibrosis and subchondral 
bone sclerosis. Alteration in the physical environment 
and release of inflammatory mediators by articular cells 
(under disease conditions) leads to acidosis. Cartilage 
matrix synthesis has a bimodal response to alterations in 
extracellular pH with optimal synthesis occurring between 
pH 7.0–7.2, and synovial fluid acidosis occurs in OA and 
rheumatoid arthritis, suggesting that pH and hypoxia may 
have an important role in maintaining cartilage integrity.7 It 
is possible that ‘correction’ of underlying systemic metabolic 
acidosis resulting from ‘Western-style’ eating habits may 
play a role.6,13,14
Conclusion
Dietary supplementation with MF, which contains organic 
anions in the form of citrate salts, significantly relieved 
the symptoms and signs of OA of the hands. Based on 
the study outcome, MF may be considered a safe and 
effective, non-allopathic therapeutic modality, alone or as 
an adjunct to other interventions, in the management of 
this common degenerative disease. Further research based 
on comorbidity factors might be warranted. These are 
short-term findings, and long-term studies are required to 
evaluate the influence of MF on bone and joint physiology 
and pathology.
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